Discovery calls for Series A companies: the 90-day install for healthcare and life sciences in Latin America
The exact 90-day plan for standing up discovery calls at Series A — the point where the founder can no longer be every function. Written for commercial leaders at healthtech, medtech, and life-sciences companies in Latin America.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Latin America. In this market, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms, so the way you install discovery calls has to be shaped to that reality from day one.
Series A is the moment discovery calls stops being optional. The founder has to step out of some of the work, the plan requires a defensible growth number, and every quarter compounds toward the next raise.
Day 1 to 30: diagnosis and instrumentation. Name the constraint, write the ICP, wire discovery-to-opportunity conversion into the board pack.
Day 31 to 60: first live cycle at 20% of planned volume. Founder still in every review. Kill criteria written and enforced.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Latin America it is compounded by the fact that local partnership depth, not marketing spend is what actually gates growth. Discovery calls is only useful here when it is pointed at both constraints at once.
Day 61 to 90: ramp to full volume, hire the first dedicated operator, and hand off ops. Founder retains strategy and the weekly review.
By day 90 the metric is legible and the trajectory is defensible. This is what turns a Series A story into a Series B round.
Trap most Series A companies fall into: reading a script instead of running a diagnosis. It usually shows up around day 45 when the founder tries to hire ahead of the model.
The Series A version of discovery calls looks small compared to what you will build at Series B. That is the point — it is a foundation, not a monument.
Concretely for healthcare and life sciences in Latin America: the healthcare teams that install this get past procurement instead of dying in it, and one properly-installed LATAM account becomes a reference across the region. That is the reason it is worth installing discovery calls deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Sales · healthcare · LATAM — answered
- Does discovery calls work for healthcare and life sciences in Latin America?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms. The healthcare teams that install this get past procurement instead of dying in it.
- Should we start discovery calls before Series A?
- Yes if the founder has time; the Series A version is the same model at higher spend.
- How much of the round should fund discovery calls?
- Meaningful — often 20–30% of the growth line — but only after diagnosis.
- When do we hire the first discovery calls operator?
- Around day 60, once the model has run one full cycle with the founder.
- What Series A trap should we avoid?
- Reading a script instead of running a diagnosis — usually a premature senior hire.
- What is the LATAM-specific pitfall when running discovery calls for healthcare?
- Importing a playbook that was built for another market. In Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms — the install has to reflect that.
Growth Broker editorial
Filed under sales · healthcare · latam